C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: Evidence that C-reactive protein is a procoagulant

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 10, 2005, Pages 2216-2221

  Singh, Uma ^a   Devaraj, Sridevi ^a   Jialal, Ishwarlal ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

C reactive protein; Endothelial cells; Inflammation; Procoagulant; Tissue plasminogen activator

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN RECEPTOR ANTAGONIST; INTERLEUKIN 1BETA; NITRIC OXIDE DONOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; SUPEROXIDE DISMUTASE; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

AORTA; AORTA ATHEROSCLEROSIS; ARTICLE; FIBRINOLYSIS; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THROMBOSIS; VASCULAR ENDOTHELIUM;

AORTA; ATHEROSCLEROSIS; BLOOD COAGULATION; C-REACTIVE PROTEIN; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FIBRINOLYSIS; HUMANS; RNA, MESSENGER; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 26244467021     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000183718.62409.ea     Document Type: Article

References (45)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
2. Ridker PM. High-sensitivity CRP: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813-1818.
3. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that CRP decreases eNOS expression and bioactivity in HAEC. Circulation. 2002;106:1439-1441.
4. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self-fulfilling prophecy: CRP attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913-919.
5. Venugopal SK, Devaraj S, Jialal I. CRP decreases prostacyclin release from HAEC. Circulation. 2003;108:1676-1678.
6. Devaraj S, Xu DY, Jialal I. C-reactive protein increases PAI-1-expression and activity in HAEC: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003;107:398-404.
7. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. CRP induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82:513-520.
8. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, Fay WP, Simon DI, Edelman ER. Increased thrombosis after arterial injury in human CRP transgenic mice. Circulation. 2003;108:512-515.
9. Schleef RR, Bevijacqua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tPA and PAI-1. J Biol Chem. 1988;263:5797-5803.
10. Wun TC, Capuano A. Initiation and regulation of fibrinolysis in human plasma at the PA level. Blood. 1987;69:1354-1362.
11. Schrauwen Y, De Vries REM, Kboistra T, Emeis JJ. Acute release of tPA from endothelium: regulatory mechanisms and therapeutic target. Fibrinolysis. 1994;8:8-13.
12. Speidl WS, Zeiner A, Nikfardjam M, Geppert A, Jordanova N, Niessner A, Zorn G, Maurer G, Schreiber W, Wojta J, Huber K. An increase of CRP is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. J Am Coll Cardiol. 2005;45:30-34.
13. Aikens ML, Grenett HE, Benza RL, Tabengwa EM, Davis GC, Booyse FM. Alcohol-induced upregulation of PA and fibrinolytic activity in cultured human ECs. Alcohol Clin Exp Res. 1998;22:375-381.
14. Han KH, Hong KH, Park JH, Ko J, Kang D. CPP promotes monocyte chemoattractant protein-1 mediated chemotaxis through upregulating CCR-2 expression in human monocytes. Circulation. 2004;109: 2566-2571.
15. Zouaoui Boudjeltia K, Piagnerelli M, Brohee D, Guillaume M, Gauchie P, Vincent JL, Remacle C, Bouckaert Y, Vanhaeverbeek M. Relationship between CRP arid hypofibrinolysis: Is this a possible mechanism to explain the association between CRP and outcome in critically ill patients? Thromb J. 2004;2:7-12.
16. Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A. Relationships between ECLT and the plasma levels of tPA and PAI-1. Thromb Haemost. 1990;63:82-86.
17. Devaraj S, O'keefe G, Jialal I. Defining the pro-inflammatory phenotype using high sensitive CRP as the biomarker. J Clin Endocrinol Metab. 2005;90:4549-4554.
18. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant TNF induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of IL-1. Proc Natl Acad Sci USA. 1986;83:4533-4537.
19. Francis RB Jr., Neely S. Inhibition of endothelial secretion of tPA and its rapid inhibitor by agents which increase intracellular cyclic AMP. Biochim Biophys Acta. 1989;1012:207-213.
20. Kaji T, Yamamoto C, Sakamoto M, Koizumi F. Endothelin modulation of tPA release from human vascular ECs in culture. Blood Coagul Fibrinolysis. 1992;3:5-10.
21. Shatos MA, Doherty JM, Stump DC, Thompson EA, Collen D. Oxygen radicals generated during anoxia followed by reoxygenation reduce the synthesis of tPA and PAI-1 in human EC culture. J Biol Chem. 1990; 265:20443-20448.
22. Smith DT, Hoetzer GL, Greiner JJ, Stauffer BL, DeSouza CA. Endothelial release of tPA in the human forearm: role of NO. J Cardiovasc Pharmacol. 2003;42:311-314.
23. Blann AD, Lip GY. Effects of CRP on the release of von Willebrand factor, E-selectin, thrombomoduliri and intercellular adhesion molecule-1 from HUVEC. Blood Coagul Fibrinolysis. 2003; 14:335-340.
24. Trion A, de Maat MP, Jukema JW, van der Laarse A, Maas MC, Offerman EH, Havekes LM, Szalai AJ, Princen HM, Emeis JJ. No effect of CRP on early atherosclerosis development in apolipoprotein E*3-leiden/human CRP transgenic mice. Arterioscler Thromb Vasc Biol. 2005;25:1635-1640.
25. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA, Pepys MB. Transgenic human CRP is not proatherogenic in apo E-deficient mice. Proc Natl Acad Sci USA. 2005;102:8309-8314.
26. Mold C, Nakayama S, Holzer TJ, Gewurz H, Du Clos TW. C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med. 1981;154:1703-1708.
27. Xia D, Samols D. Transgenic mice expressing rabbit CRP are resistant to endotoxemia. Proc Natl Acad Sci USA. 1997;94:2575-2580.
28. Szalai AJ, VanCott JL, McGhee JR, Volanakis JE, Benjamin WH Jr. Human CRP is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect Immun. 2000;68:5652-5656.
29. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB. CRP and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999; 190:1733-1740.
30. Gill R, Kemp JA, Sabin C, Pepys MB. Human CRP increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J Cereb Blood Flaw Metab. 2004;24:1214-1218.
31. Stroke rt-PA Stroke Study Group: The National Institute of Neurological Disorders. tPA for acute ischemic stroke. N Engl J Med. 1995;333: 1581-1587.
32. Devaraj S, Du Clos TW, Jialal I. Binding and internalization of CRP by Fc gamma receptors on HAEC mediates biological effects. Arterioscler Thromb Vasc Biol. 2005;26:1-5.
33. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of CRP across the full range of Framingham Risk Scores. Circulation. 2004;109:1955-1959.
34. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of CRP and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039-1051.
35. Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of CRP in HAEC: potential for paracrine/autocrine effects. Am J Path. 2005;166:1265-1271.
36. Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ, van den Bogaard B, Reitsma PH, Meijers JC, Hartman D, Levi M, Stroes ES. Activation of inflammation and coagulation after infusion of CRP in humans. Circ Res. 2005;96:714-716.
37. Pietila KO, Harmoinen AP, Jokinitty J, Pasternack AI. Serum CRP concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart Jl. 1996;17:1345-1349.
38. Van den Berg CW, Taylor KE, Lang D. CRP-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations. Arterioscler Thromb Vasc Biol. 2004;24: e168-e171.
39. Taylor KE, Giddings JC, van den Berg CW. CRP-induced in vitro endothelial cell activation is an artefact caused by azide and LPS. Arterioscler Thromb Vasc Biol. 2005;25:1225-1230.
40. Liu C, Wang S, Deb A, Nath KA, Katusic ZS, McConnell JP, Caplice NM. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial CRP on various human endothelial cell types in vitro. Implications of Contaminating Presence of Sodium Azide in Commercial Preparation. Circ Res. 2005;97:135-143.
41. Rydholm H, Bostrom S, Eriksson E, Risberg B. Complex intracellular signal transduction regulates tPA and PAI-1 synthesis in cultured HUVEC. Scand J Clin Lab Invest. 1995;55:323-330.
42. Ballou CP, and Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by CRP. Cytokine. 1992;4:361-368.
43. Devaraj S, Kumaresan PR, Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol. 2004;36:405-410.
44. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
45. Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum CRP and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive CRP assay. J Am Coll Cardiol. 2001;37:2036-2041.